The Trump administration has withdrawn its sweeping proposal to catch rid of rebates from executive drug plans, a White Dwelling spokesperson confirmed to POLITICO.
“Primarily essentially based on careful diagnosis and thorough consideration, the president has made up our minds to withdraw the rebate rule,” spokesperson Judd Deere acknowledged in a statement. “The Trump administration is galvanized by continuing bipartisan conversations about laws to diminish execrable drug prices imposed on the American individuals, and President Trump will care for in thoughts the usage of any and all tools to guarantee that prescription drug prices will proceed to decline.”
Story Persisted Underneath
The proposal — a centerpiece of the Trump administration’s choice to diminish drug prices — had destroy up HHS and the White Dwelling. HHS Secretary Alex Azar had argued that removal rebates would lead to diminish checklist prices, warning in April that any policy that fails to handle rebates “will merely not catch checklist prices down.” But the proposal had faced resistance from home policy chief Joe Grogan and other fiscal hawks on grounds that it used to be too costly — costing the chief just about $180 billion over a decade.
Some lawmakers moreover afraid the rule of thumb would elevate seniors’ Medicare Fragment D premiums.
Axios first reported that the White Dwelling used to be pulling the rule of thumb.
In a statement this day, HHS pointed to ongoing efforts to diminish drug prices.
“Secretary Azar is preventing alongside President Trump to diminish prescription drug prices and defend The US’s seniors,” HHS spokesperson Caitlin Oakley acknowledged. “President Trump and Secretary Azar are taking dauntless bolt to give up international free driving, watch how to soundly import decrease-tag prescription medication, empower patients with meaningful transparency, and the checklist goes on.”